Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.39
(0.0%)
AUD 0.39
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -6.37 Million AUD | -2.28% |
| 2023 | -6.23 Million AUD | -25.36% |
| 2022 | -4.97 Million AUD | -73.9% |
| 2021 | -2.85 Million AUD | -63.99% |
| 2020 | -1.74 Million AUD | 16.18% |
| 2019 | -2.08 Million AUD | -44.45% |
| 2018 | -1.44 Million AUD | -57.14% |
| 2017 | -916.47 Thousand AUD | 31.01% |
| 2016 | -1.32 Million AUD | -15.6% |
| 2015 | -1.14 Million AUD | -366.16% |
| 2014 | -246.52 Thousand AUD | 1.91% |
| 2013 | -251.31 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -2.62 Million AUD | 0.0% |
| 2024 Q2 | -3.75 Million AUD | 0.0% |
| 2024 FY | -6.37 Million AUD | -2.28% |
| 2023 Q1 | -2.01 Million AUD | -11.25% |
| 2023 Q2 | -4.02 Million AUD | -100.0% |
| 2023 FY | -6.23 Million AUD | -25.36% |
| 2023 Q3 | -1.07 Million AUD | 73.34% |
| 2023 Q4 | -2.14 Million AUD | -100.0% |
| 2022 Q2 | -3.16 Million AUD | 0.0% |
| 2022 Q4 | -1.81 Million AUD | -100.0% |
| 2022 FY | -4.97 Million AUD | -73.9% |
| 2022 Q3 | -905.28 Thousand AUD | 71.37% |
| 2021 FY | -2.85 Million AUD | -63.99% |
| 2021 Q1 | -435.94 Thousand AUD | 19.6% |
| 2021 Q2 | -1.86 Million AUD | -328.6% |
| 2021 Q3 | -495.6 Thousand AUD | 73.48% |
| 2021 Q4 | -991.21 Thousand AUD | -100.0% |
| 2020 FY | -1.74 Million AUD | 16.18% |
| 2020 Q4 | -542.22 Thousand AUD | -24.38% |
| 2020 Q3 | -435.94 Thousand AUD | 63.72% |
| 2020 Q2 | -1.2 Million AUD | 0.0% |
| 2019 Q1 | -890.05 Thousand AUD | -592.87% |
| 2019 Q4 | -300.16 Thousand AUD | 42.28% |
| 2019 Q3 | -520.06 Thousand AUD | 70.78% |
| 2019 Q2 | -1.78 Million AUD | -100.0% |
| 2019 FY | -2.08 Million AUD | -44.45% |
| 2018 Q2 | -1.31 Million AUD | -100.0% |
| 2018 Q1 | -655.82 Thousand AUD | -2513.69% |
| 2018 Q4 | -128.45 Thousand AUD | 64.32% |
| 2018 Q3 | -360.02 Thousand AUD | 72.55% |
| 2018 FY | -1.44 Million AUD | -57.14% |
| 2017 Q3 | -229.11 Thousand AUD | 75.72% |
| 2017 Q2 | -943.64 Thousand AUD | -100.0% |
| 2017 Q4 | 27.17 Thousand AUD | 111.86% |
| 2017 FY | -916.47 Thousand AUD | 31.01% |
| 2017 Q1 | -471.82 Thousand AUD | -60.29% |
| 2016 Q2 | -1.03 Million AUD | -259.94% |
| 2016 FY | -1.32 Million AUD | -15.6% |
| 2016 Q3 | -332.11 Thousand AUD | 67.88% |
| 2016 Q1 | -287.3 Thousand AUD | 67.15% |
| 2016 Q4 | -294.35 Thousand AUD | 11.37% |
| 2015 FY | -1.14 Million AUD | -366.16% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | -287.3 Thousand AUD | -4.59% |
| 2015 Q4 | -874.5 Thousand AUD | -204.39% |
| 2015 Q2 | -274.69 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 FY | -246.52 Thousand AUD | 1.91% |
| 2013 FY | -251.31 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -18.489% |
| Acrux Limited | -5.8 Million AUD | -9.935% |
| Actinogen Medical Limited | -13.04 Million AUD | 51.119% |
| AnteoTech Limited | -8.88 Million AUD | 28.2% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -16.365% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 27.096% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -339.363% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 66.658% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -41.585% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -85.541% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -164.664% |
| Biome Australia Limited | -1.67 Million AUD | -281.763% |
| Biotron Limited | -3.43 Million AUD | -85.543% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 54.028% |
| BTC Health Limited | 1.05 Million AUD | 704.217% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 49.112% |
| CSL Limited | 2.64 Billion AUD | 100.241% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 84.935% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 117.892% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 34.567% |
| Dimerix Limited | -17.07 Million AUD | 62.658% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 191.553% |
| Hexima Limited | -933.87 Thousand AUD | -582.772% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -122.609% |
| Immuron Limited | -6.93 Million AUD | 8.083% |
| Immutep Limited | -39.89 Million AUD | 84.018% |
| Imugene Limited | -149.68 Million AUD | 95.74% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -288.365% |
| Memphasys Limited | -4.44 Million AUD | -43.543% |
| Nanollose Limited | -1.15 Million AUD | -451.312% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 104.059% |
| Noxopharm Limited | -3.57 Million AUD | -78.2% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 2066.694% |
| Nyrada Inc. | -1.38 Million AUD | -359.969% |
| Orthocell Limited | -7.18 Million AUD | 11.207% |
| PharmAust Limited | -9.03 Million AUD | 29.407% |
| Patrys Limited | -3.53 Million AUD | -80.162% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 89.129% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 22.6% |
| PYC Therapeutics Limited | -37.72 Million AUD | 83.098% |
| Race Oncology Limited | -13.81 Million AUD | 53.86% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 86.702% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 63.898% |
| Starpharma Holdings Limited | -8.16 Million AUD | 21.908% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 222.361% |
| Tissue Repair Ltd | -4.13 Million AUD | -54.086% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 82.564% |